SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending following reports that John Ternus is a leading candidate to succeed Tim Cook, sparking community debate about the company's future direction. This news emerges as the stock experiences a notable downturn, prompting many to call it an oversold 'buy the dip' opportunity while others express skepticism over Apple's competitive position in AI, especially after Google recently surpassed its market capitalization.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving positive FDA feedback, confirming that existing clinical trial data for its lead candidate, sonelokimab, is sufficient for a Biologics License Application in hidradenitis suppurativa. This regulatory clarity has significantly de-risked the asset, fueling intense community discussion about potential buyout offers and the stock's substantial undervaluation compared to previous bids from major pharmaceutical companies.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending amidst intense debate following recent preliminary financial guidance that projected lower DefenCath revenue in future years, sparking significant frustration and accusations of mismanagement among some retail investors. This negative sentiment is contending with community members who view the sell-off as an overreaction, pointing to strong real-world evidence confirming DefenCath's efficacy and the company's diversified pipeline as indicators of an undervalued long-term opportunity. The community remains deeply divided over the stock's immediate future versus its underlying value.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is a focal point for investors following a strong earnings report that exceeded revenue and profitability expectations, driven by rapid expansion into high-performance computing. The community is actively discussing the company's robust pipeline, including advanced negotiations for significant new data center capacity, which could substantially increase its contracted revenue and potentially pressure short positions. This momentum positions the company as a key infrastructure provider in the booming AI sector.

flyExclusive, Inc. engages in owning and operating jet aircraft for private jet passengers. It manages all aspects of the customer experience, in-house maintenance, repair, and overhaul services, including paint, interiors, and avionics capabilities. The company was founded by Thomas James Segrave, Jr. in 2015 and is headquartered in Kinston, NC.

flyExclusive Inc. - Ordinary Shares - Class A

flyExclusive Inc. is trending sharply after announcing a partnership to become an authorized Starlink Aviation dealer, integrating SpaceX's high-speed internet into its private jet fleet and MRO services. This news has ignited significant community excitement, with many speculating on substantial price appreciation due to the low float and its connection to the Starlink ecosystem. The stock is seeing extreme volatility and multiple trading halts as investors weigh the long-term impact of this strategic move against its rapid ascent.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending amid a significant surge in trading volume and price action, with community members enthusiastically discussing a potential breakout and a "next leg up." Bullish sentiment is fueled by anticipation of key 2026 developments in decentralized AI, DePIN, and secure data monetization, alongside its strong regulatory standing in Japan. Conversely, some participants remain wary, labeling the current rally as a "pump and dump" and questioning its sustainability given past volatility.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. (ACON) is trending after providing an upbeat corporate outlook, highlighting accelerating Nociscan AI platform adoption and a strong, debt-free balance sheet. The community is actively discussing the stock's exceptionally low float and substantial cash per share, igniting widespread speculation for a significant short squeeze. Investors are optimistic about its AI-driven healthcare solution and anticipate further upside as clinical trials progress.

iPower, Inc. engages in the online retail and supply of consumer home, garden, in-home farming, pet, and wellbeing products. It sells its brands such as Simple Deluxe, YSSOA, Zenhydro, Flourish, iPOWER, iFarm, FluffyDream, ScratchMe, and HealSmart through zenhydro.com, simpledeluxe.com, and various third-party online platforms. The company offers grow light systems, advanced heating, ventilation and air conditioning (HVAC) systems, water pumps, heaters, chillers and filters, nutrient and fertilizer delivery systems, and various growing media typically made from soil, rock wool or coconut fiber. It also provides home goods supplies including commercial fans, floor and wall fans, storage and shelving units, and chairs. The company was founded by Chenlong Tan and Allan Huang on April 11, 2018 and is headquartered in Rancho Cucamonga, CA.

iPower Inc

iPower Inc. is currently trending with high community interest, largely fueled by its extremely low public float after a recent capital structure change, leading to active speculation about a potential short squeeze. Investors are also discussing the company's strategic foray into digital assets, including initial purchases of Bitcoin and Ethereum, which is generating varied perspectives. This combination of tight market supply and a new crypto treasury strategy makes it a highly debated stock.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is currently experiencing significant market volatility, primarily driven by a recent Bank of America downgrade and intense community debate surrounding its strategy in the competitive weight loss market, particularly concerning GLP-1 offerings. Despite strong arguments from bulls about consistent revenue growth, international expansion, and high short interest, bears are focusing on the stock's recent price decline and valuation concerns. This has led to a highly polarized discussion as investors weigh long-term growth against immediate market sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$SPX $SPY 2019 Rate positions on #Fed Summary of table from prior message: 1 vote at 2.625% (1 hike), 8 at 2.375% (middle of CURRENT Rate target range - NO CUTS) and 7 at 1.875% - essentially 2 cuts below here.  Net for 2019 is 9 (same or higher rates) vs. 7 (2 cuts) NOT A CLEAR WIN for those wanting rate cuts if you add up the votes.  $GLD $TLT $TNX $IWM $IJH

$SPX $SPY $IWM $IJH $GLD $TLT $TNX #Fed  Removed word &quot;patient&quot; says &quot;uncertainties have increased&quot; will &quot;Act as appropriate to support expansion&quot; 8 of them  forecasting rate cut - 7 2 cuts 2/

StockTwits Web

S&P 500 Index

SPDR Gold Shares ETF

iShares Core S&P Mid-Cap ETF

iShares Russell 2000 ETF

iShares 20+ Year Treasury Bond ETF

CBOE 10-Year Treasury Yield Index

David Durand

 Summary of table from prior message: 1 vote at 2.625% (1 hike), 8 at 2.375% (middle of CURRENT Rate target range - NO CUTS) and 7 at 1.875% - essentially 2 cuts below here.  Net for 2019 is 9 (same or higher rates) vs. 7 (2 cuts) NOT A CLEAR WIN for those wanting rate cuts if you add up the votes.  